Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Common Equity (2016 - 2025)

Ligand Pharmaceuticals' Common Equity history spans 16 years, with the latest figure at $1.0 billion for Q4 2025.

  • For Q4 2025, Common Equity rose 22.49% year-over-year to $1.0 billion; the TTM value through Dec 2025 reached $1.0 billion, up 22.49%, while the annual FY2025 figure was $1.0 billion, 22.49% up from the prior year.
  • Common Equity for Q4 2025 was $1.0 billion at Ligand Pharmaceuticals, up from $950.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $1.0 billion in Q4 2025 and bottomed at $597.5 million in Q4 2022.
  • The 5-year median for Common Equity is $799.0 million (2022), against an average of $784.9 million.
  • The largest annual shift saw Common Equity dropped 27.24% in 2022 before it rose 25.94% in 2024.
  • A 5-year view of Common Equity shows it stood at $821.2 million in 2021, then decreased by 27.24% to $597.5 million in 2022, then grew by 17.31% to $700.9 million in 2023, then rose by 18.48% to $830.4 million in 2024, then grew by 22.49% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for LGND's Common Equity are $1.0 billion (Q4 2025), $950.2 million (Q3 2025), and $827.3 million (Q2 2025).